Relatlimab and nivolumab in the treatment of melanoma.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36563660.
- Also identified by DOI 10.1016/j.cell.2022.12.003.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Combined LAG-3 and PD-1 blockade is an emerging strategy for the treatment of melanoma. Tawbi et al. and Amaria et al. report in The New England Journal of Medicine and Nature respectively on two clinical trials evaluating relatlimab and nivolumab as front-line treatment for metastatic, and resectable, high-risk, node-positive melanoma.
Medical subject headings
- Nivolumab
- Melanoma